Filipendula ulmaria In 1897, Felix Hoffmann created a synthetically altered version of salicin, derived from the species, which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named aspirin by Hoffmann's employer Bayer AG after the old botanical name for meadowsweet, "Spiraea ulmaria". This gave rise to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). A natural black dye can be obtained from the roots by using a copper mordant. A tea made from "Filipendula ulmaria" flowers or leaves has been used in traditional Austrian herbal medicine for the treatment of rheumatism, gout, infections,
Obeticholic acid synthesis, have been found in this condition. FGF19 is potently stimulated by bile acids and especially by OCA. A proof of concept study of OCA (25 mg/d) has shown clinical and biochemical benefit. On February 1, 2018, the FDA updated label warnings for Obeticholic acid to better explain recommended dosing. According to the agency, misunderstanding led some health care professionals to improperly dose the drug on a daily basis rather than weekly, which can increase the risk of liver damage. Obeticholic acid Obeticholic acid (abbreviated to OCA, trade name Ocaliva), is a semi-synthetic bile acid analogue which has the chemical